Fixed price, unfixed volume: the company is locked into a rate while the amount it can sell against it is climbing
The model's full reasoning — Q2 2018 call → NO我们根据提供的财报电话会议记录,判断是否存在一个情况:公司收入的价格/费率已经固定,而数量正在上升,且报告的结果反映的是较低的数量水平。 在记录中,管理层讨论了多个话题,包括钙敏感受体激动剂(Calcimimetics)的过渡、护理协调(Care Coordination)的利润率、美国ESRD支付规则等。但我们需要寻找一个具体的情况,其中价格已锁定,而数量正在增加。 关键点:管理层提到“Calcimimetics”从Part D转向Part B,涉及药房到诊所的过渡。他们表示这是一个滴定过程,从低剂量开始逐步增加。这暗示着每单位治疗的价格可能由医保设定(Part B),而数量(患者使用剂量)正在逐步增加。但管理层没有明确说价格已固定,而是说这是一个医疗决策,基于算法,逐步增加剂量。这更像是数量(剂量)在增加,而价格(每剂量)可能由医保支付标准决定,但未明确说明价格已锁定。 另一个可能:美国ESRD支付规则(PPS)的提议增加1.7%,但这是未来费率,尚未最终确定,且管理层没有说数量在增加。 关于护理协调,管理层提到收入下降,但利润率改善,没有提到数量上升。 关于产品业务,增长是恒定的,但价格和数量未明确区分。 最接近的是Calcimimetics的过渡:管理层说“我们可能处于两到四个季度的过程中”,并提到“滴定,逐步增加剂量”,这暗示着随着时间推移,每个患者的剂量(数量)会增加,而价格(每剂量)可能由医保支付,但管理层没有明确说价格已固定。他们提到“收入和治疗成本”受此影响,但未明确说价格已锁定。 此外,管理层提到“我们预计收入每治疗将持平或略有下降,成本每治疗将持平或略有上升,不包括Calcimimetics”,这表明价格(每治疗收入)是波动的,而不是固定的。 因此,没有明确的情况表明价格已固定而数量正在上升。管理层更多是在讨论价格压力(如商业支付者收入下降)和数量增长(如患者增长),但价格不是固定的。 所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| JLL | Jones Lang LaSalle Incorporated | Q3 2023 | 2023-11-02 | F |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| SLF | Sun Life Financial Inc. | Q1 2023 | 2023-05-12 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| FI | Fiserv, Inc. | Q4 2017 | 2018-02-27 | C |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FIX | Comfort Systems USA, Inc. | Q1 2017 | 2017-04-30 | A |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
ABR · Q4 2016 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing the Agency Business servicing portfolio at $13.6 billion with a fixed 48 basis point weighted average servicing fee that is already contracted and recurring. They explicitly note the portfolio is growing through recent originations, including $700 million closed in December, which will drive higher servicing income in Q 1. Management states they expect the portfolio to generate over $65 million annually and references growth from 2015 levels, indicating the reported Q4 results reflect a lower average volume during the quarter while the settled economics now scale with the increasing volume arriving in Q1.
FIX · Q1 2017 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing a situation where pricing is stable and contracts (backlog) lock in rates, while volume is rising through backlog growth and upcoming organic work. The Q1 results reflect lower seasonal volume, with the backlog supporting higher throughput ahead. This fits the criteria of settled rates on meaningful contracted business with 13% backlog increase driving volume step-up.
CHE · Q3 2022 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES Management describes Medicare reimbursement rates as already fixed by regulation (CMS), with the volume side now rising through a first significant expansion of clinical staff and patient capacity since the pandemic, plus strengthening admissions and weekly ADC growth in the second half. The reported quarter reflects lower volume (ADC down 4.